Warby Parker Inc. Stock

Equities

WRBY

US93403J1060

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-19 pm EDT 5-day change 1st Jan Change
12.05 USD +1.43% Intraday chart for Warby Parker Inc. -8.85% -14.54%
Sales 2024 * 755M Sales 2025 * 851M Capitalization 1.4B
Net income 2024 * -11M Net income 2025 * 10M EV / Sales 2024 * 1.53 x
Net cash position 2024 * 252M Net cash position 2025 * 291M EV / Sales 2025 * 1.31 x
P/E ratio 2024 *
-90.2 x
P/E ratio 2025 *
119 x
Employees 2,807
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.31%
More Fundamentals * Assessed data
Dynamic Chart
Warby Parker Insider Sold Shares Worth $290,216, According to a Recent SEC Filing MT
Warby Parker Shares Drop After Reporting Q4 Net Loss Narrows, Net Revenue Gains MT
Transcript : Warby Parker Inc., Q4 2023 Earnings Call, Feb 28, 2024
Warby Parker Inc. Provides Earnings Guidance for the Full Year 2024 CI
Earnings Flash (WRBY) WARBY PARKER Reports Q4 Revenue $161.9M, vs. Street Est of $160.8M MT
Warby Parker Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Warby Parker Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Warby Parker Inc. and Warby Parker Retail, Inc. Terminates Prior Credit Agreement and Enters into A Credit Agreement with JP Morgan Chase Bank, N.A., Citibank, N.A. and Other Lenders CI
Morgan Stanley Adjusts Warby Parker Price Target to $13 From $12, Maintains Equal Weight Rating MT
Warby Parker Insider Sold Shares Worth $328,047, According to a Recent SEC Filing MT
Warby Parker Insider Sold Shares Worth $591,761, According to a Recent SEC Filing MT
Warby Parker Insider Sold Shares Worth $591,761, According to a Recent SEC Filing MT
Transcript : Warby Parker Inc. Presents at 2023 Morgan Stanley Global Consumer and Retail Conference, Dec-06-2023 11:00 AM
Goldman Sachs Cuts Price Target on Warby Parker to $14 From $15, Keeps Neutral Rating MT
Morgan Stanley Trims Price Target on Warby Parker to $12 From $13 on Higher Weighted Average Cost of Capital, Keeps Equalweight Rating MT
More news
1 day-1.74%
1 week-12.26%
Current month-12.71%
1 month+2.24%
3 months-10.34%
6 months-16.22%
Current year-15.74%
More quotes
1 week
11.81
Extreme 11.805
13.58
1 month
11.67
Extreme 11.67
14.08
Current year
11.35
Extreme 11.35
15.25
1 year
9.83
Extreme 9.83
16.49
3 years
9.50
Extreme 9.5
60.30
5 years
9.50
Extreme 9.5
60.30
10 years
9.50
Extreme 9.5
60.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 43 08-12-31
Chief Executive Officer 54 09-05-06
Director of Finance/CFO 51 10-12-31
Members of the board TitleAgeSince
Director/Board Member 63 21-07-31
Director/Board Member 60 18-02-28
Director/Board Member 74 21-07-31
More insiders
Date Price Change Volume
24-04-19 12.05 +1.43% 1 008 738
24-04-18 11.88 -1.74% 1,070,521
24-04-17 12.09 -4.12% 995,583
24-04-16 12.61 -3.22% 1,213,476
24-04-15 13.03 -1.44% 882,982

Delayed Quote Nyse, April 18, 2024 at 04:00 pm EDT

More quotes
Warby Parker Inc. is a lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. It offers holistic vision care by selling eyewear products and providing optical services directly to consumers through its retail stores and e-commerce platform. It sells a range of prescription and non-prescription eyewear, including glasses, sunglasses, and contact lenses. Its customers can customize their prescription lenses with a variety of options, including single-vision, progressive, light-responsive, blue-light-filtering, and non-prescription lenses. It also offers in-house technologies like Virtual Vision Test and Virtual Try-On to enhance the overall customer experience. It sells its own brand of contacts, Scout by Warby Parker, and third-party contact lenses; this allows it to provide customers a vision care offering. Its Website and mobile app make it easy for its customers to browse, virtually try on, and purchase glasses.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
11.88 USD
Average target price
15.17 USD
Spread / Average Target
+27.67%
Consensus